NCT03900325View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

PHASE2UnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

January 31, 2020

Study Completion Date

April 30, 2020

Conditions
Diabetic Gastroparesis
Interventions
DRUG

Nimacimab

2.5 mg/kg

DRUG

Placebo

0.9% sodium chloride

Trial Locations (5)

33014

Panax Clinical Research, Miami

33183

International Research Associates, LLC, Miami

37421

ClinSearch, Chattanooga

55905

Mayo Clinic, Rochester

67205

PRN of Kansas, Wichita

Sponsors
All Listed Sponsors
lead

Bird Rock Bio, Inc.

INDUSTRY

NCT03900325 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis | Biotech Hunter | Biotech Hunter